Trial Profile
Monitoring EBV Load in Rheumatoid Arthritis Patients Treated With New Imunosuppressive Drugs ; Orencia (Abatacept) and RoActemra (Tocilizumab).
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2017
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- 13 Oct 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 06 Aug 2009 New trial record